Immune Modulation

Our approach to advancing next-generation treatments for autoimmune diseases and inflammation is based on regulation of T cells. Many subtypes of T cells, with their unique characteristics and functions, are known to mediate Th1 and Th2 type inflammatory diseases. By modulating the functions of each of these cell populations, it is possible to treat diseases with a high degree of specificity and to avoid unwanted side-effects due to unintended alternations to unrelated cells and tissues.

CONNECT has built a drug discovery platform based on our insight in the modulation of T cell functions. In this platform, potential drug candidates are screened with high-throughput to identify leads that effectively regulate certain cell populations.

CBP-307 is such a subpopulation-specific T cell immune modulator. It activates and induces internalization of S1P1, a receptor expressed the native and central memory T cells. In this process, the drug prevents their migration out of lymph nodes and reduce the entry of these T cells into the inflamed tissues. The pathway CBP-307 modulates is the Th1 pathway, associated with many autoimmune diseases.

CBP-201 is another immune modulator that regulates certain populations of T cells. The antibody binds IL-4Ra, and blocking the signaling of both IL-4 and IL-13, two important and functionally overlapping cytokines that stimulate the Th2 pathway. Therefore, CBP-201 is expected to treat Th2 type diseases such as asthma and atopic dermatitis without at the same time affecting the Th1 pathway, thereby avoiding unwanted sides due to global immune suppression.


TEL/FAX: 0512-53577866

E-MAIL: qchang@connectpharm.com

ADD: 10th Floor, XiangTang Development Building #3 ChaoYang Dong Road, Taicang,Jiangsu Province, China ,215400

Copyright: Suzhou Connect Biopharmaceuticals, Ltd.

Technical support: Epower